A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
A phase 3 trial testing HMPL-306 in acute myeloid leukaemia, now recruiting.
Overview
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukaemia is a phase 3 interventional study registered as NCT06387069, led by Hutchmed, and recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukaemia (R/R AML). Planned enrolment is 316 participants (estimated). The study started in 2024-04-26 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Shares Hutchmed and the tag ctgov-ingest.
- TrialHMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Shares Hutchmed and the tag ctgov-ingest.
- TrialA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Shares Hutchmed and the tag ctgov-ingest.
- TrialHEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TrialA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Shares Acute myeloid leukaemia and the tag ctgov-ingest.
- TreatmentLB4330
Shares Hutchmed and the tag ctgov-ingest.
- TreatmentLB1410
Shares Hutchmed and the tag ctgov-ingest.
- TreatmentHMPL-760
Shares Hutchmed and the tag ctgov-ingest.